Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

Phase 3 BATTMAN Trial

More Like This

France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update